Title: Rytary/IPX066 (Parkinson’s Disease) – Market analysis to 2022
1Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_marketoptimizer.org with
your contact details and questions if any.
- Published Mar 2014
- Single User PDF US 3495
- Corporate User PDF US 10485
2Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
- Parkinsons disease is a progressive condition
that is characterized by bradykinesia, muscular
rigidity, tremor, and postural instability. As
the second most common neurodegenerative
disorder, Parkinsons disease may affect
individuals of any age but prevalence is
increased with age and it is most common in the
elderly. Dopaminergic therapies have been fairly
effective in treating bradykinesia, but several
unmet needs remain. Some needs will be met during
the forecast period from 2012-2022, while others,
such as the need for disease-modifying drugs,
will remain. - Researcher expects that advancements will be
made in levodopa administration and that four new
molecular entities will be introduced to the
market by 2022, these factors along with
increased patient numbers from an aging
population will drive the market during the
forecast period.
Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
3Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
- Rytary, also known as IPX066, is a levodopa-based
product for the treatment of early and advanced
Parkinsons disease. It was developed by the
generics manufacturer Impax Laboratories and
contains a capsule with different-sized beads
that dissolve at different rates, releasing a 14
ratio of carbidopa levodopa - Scope
- Overview of Parkinsons disease, including
epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an
overview on the competitive landscape. - Detailed information on Rytary including product
description, safety and efficacy profiles as well
as a SWOT analysis. - Sales forecast for Rytary for the top six
countries from 2012 to 2022. - Sales information covered for the US, France,
Germany, Italy, Spain and the UK.
Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
4Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
- Reasons to buy
- Understand and capitalize by identifying products
that are most likely to ensure a robust return - Stay ahead of the competition by understanding
the changing competitive landscape for
Parkinsons disease - Effectively plan your MA and partnership
strategies by identifying drugs with the most
promising sales potential - Make more informed business decisions from
insightful and in-depth analysis of Rytary
performance - Obtain sales forecast for Rytary from 2012-2022
in the top six countries (the US, France,
Germany, Italy, Spain and the UK). - Get a detailed report at http//www.marketoptimize
r.org/rytaryipx066-parkinsons-disease-forecast-and
-market-analysis-to-2022.html .
Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
5Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
- About Us
- marketoptimizer.org is an online market research
reports library of 250,000 in-depth studies of
over 5000 micro markets. Our database includes
reports by leading publishers from across the
globe. We provide 24/7 online and offline support
service to our customers. marketoptimizer.org
also offers company data, country profiles,
trends, information and analysis on the sector of
your interest. - Visit Us _at_
- http//www.marketoptimizer.org
- Follow Us
Call Now 1 888 391 5441 Email sales _at_
sales_at_marketoptimizer.org